(TELA) Tela Bio - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8723811084

TELA: Tissue Matrix, Hernia Repair, Abdominal Reconstruction, Robotic Surgery

TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions designed to preserve and restore patient anatomy. The company offers a range of OviTex Reinforced Tissue Matrix products, including hernia repair and abdominal wall reconstruction solutions, as well as OviTex PRS for plastic and reconstructive surgery. Additionally, OviTex is available for laparoscopic and robotic-assisted procedures, utilizing sterile reinforced tissue matrices derived from ovine rumen with polypropylene fibers. The company distributes its products primarily through a direct sales force in the United States. Founded in 2012, TELA Bio is headquartered in Malvern, Pennsylvania.

The companys product portfolio addresses unmet clinical needs in hernia repair and reconstructive surgery, focusing on minimizing complications and improving surgical outcomes. Its OviTex line combines natural and synthetic materials to provide strength and facilitate tissue regeneration, making it suitable for a variety of surgical applications. TELA Bios direct sales model allows for targeted outreach to surgeons and healthcare providers, ensuring precise alignment with clinical demands.

Based on the provided data, here is a 3-month forecast:

Technical indicators suggest TELA shares may face near-term headwinds, as the stock price (2.34) is below its 20-day (2.63) and 50-day (2.72) moving averages, signaling potential weakness. The 200-day moving average (3.46) further indicates a downtrend. Average daily volume (143,688) and ATR (0.17) suggest manageable volatility. On the fundamental side, TELAs market cap (96.50M) and P/S ratio (1.41) align with its current growth stage, while the high P/B ratio (22.99) and negative P/E suggest elevated valuations relative to book value. The exceptionally high RoE (662.04) highlights strong profitability per equity dollar, though the lack of forward P/E indicates uncertainty about future earnings. Overall, TELA may experience short-term price pressure but could stabilize as clinical adoption of its products progresses.

Additional Sources for TELA Stock

TELA Stock Overview

Market Cap in USD 96m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Supplies
IPO / Inception 2019-11-08

TELA Stock Ratings

Growth 5y -86.5%
Fundamental 10.6%
Dividend 0.0%
Rel. Strength Industry -56.9
Analysts 4.5/5
Fair Price Momentum 1.61 USD
Fair Price DCF -

TELA Dividends

No Dividends Paid

TELA Growth Ratios

Growth Correlation 3m -82.9%
Growth Correlation 12m -81.3%
Growth Correlation 5y -86.6%
CAGR 5y -23.75%
CAGR/Max DD 5y -0.26
Sharpe Ratio 12m -2.50
Alpha -62.90
Beta 0.33
Volatility 47.24%
Current Volume 119.9k
Average Volume 20d 156.2k
What is the price of TELA stocks?
As of March 16, 2025, the stock is trading at USD 2.35 with a total of 119,874 shares traded.
Over the past week, the price has changed by -2.89%, over one month by -9.96%, over three months by -15.77% and over the past year by -56.56%.
Is Tela Bio a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Tela Bio is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 10.61 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TELA as of March 2025 is 1.61. This means that TELA is currently overvalued and has a potential downside of -31.49%.
Is TELA a buy, sell or hold?
Tela Bio has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy TELA.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for TELA stock price target?
According to ValueRays Forecast Model, TELA Tela Bio will be worth about 1.7 in March 2026. The stock is currently trading at 2.35. This means that the stock has a potential downside of -25.96%.
Issuer Forecast Upside
Wallstreet Target Price 9.5 304.3%
Analysts Target Price 9.5 304.3%
ValueRay Target Price 1.7 -26%